Original Source(s)
Related Content
FDA Approves New Treatment for Thyroid Eye Disease
Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.
June 29, 2026
-
3 min
Emphasis on Vitreoretinal Surgery
Upfront: Monthly reflection by Editor in Chief Diana V. Do, MD.
July 1, 2026
-
3 min
New Immune Target in Dry Eye
Investigators say rexinoid therapy may represent a new class of dry eye treatment focused on regenerative immune signaling
June 30, 2026
-
3 min